TP53 and Barrett esophagus: Furthermore, many genomic loci had LOH mutations in non-dysplastic targets (IM, IND) in comparable frequency to CDKN2A and TP53 associated mutations, suggesting that other genomic loci beyond those related to TP53 and CDKN2A are present at even early stages of BE.